Prospects for the prevention of dementia

Australasian Journal on Ageing

Volumn 21, Issue 1, 2002, Pages 9-13

  Jorm, Anthony F ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002441304     PISSN: 14406381     EISSN: 17416612     Source Type: Journal    
DOI: 10.1111/j.1741-6612.2002.tb00409.x     Document Type: Review

References (32)

1. Skoog I. Vascular aspects in Alzheimer's disease Journal of Neural Transmission 2000; Suppl 59: 37-43.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health 1998; 88: 1337-1342.
3. Schenk D, Seubert P, Lieberburg I, Wallace J. p-peptide immunization: A possible new treatment for Alzheimer disease. Archives of Neurology 2000; 57: 934-936.
4. McGeer PL, Schulze M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
5. Yaffe K, Saway, G, Lieberburg, I, Grady 0. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. Journal of the American Medical Association 1998; 279: 688-695.
6. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Controlled Clinical Trials 1998; 19: 604-621.
7. Henderson VW, Paganini-Hill A, Miller EL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
8. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Journal of the American Medical Association 2000; 283: 1007-1015.
9. Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Disease and Associated Disorders. 1998; 12: 121-126.
10. Paleologos M, Cumming RG, Lazarus R. Cohort study of vitamin C intake and cognitive impairment. American Journal of Epidemiology 1998; 148: 45-50.
11. Perrig WJ, Perri, P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. Journal of the American Geriatrics Society 1997; 45: 718-724.
12. Kalmijn S, Feskens EJM, Launer LJ, Kromhout 0. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. American Journal of Epidemiology 1997; 145: 33-41.
13. Sobel E, Dunn M, Davanipou, Z, Qian Z, Chui HC. Elevated risk of Alzheimer's disease among workers with likely electromagnetic field exposure. Neurology 1996; 47: 1477-1481.
14. Feychting M, Pedersen NL, Svedber, P, Floderus B, Gatz, M. Dementia and occupational exposure to magnetic fields. Scandinavian Journal of Work Environment and Health 1 998; 24: 46-53.
15. Savitz DA, Checkoway H, Loomi, DP. Magnetic field exposure and neurodegenerative disease mortality among electric utility workers. Epidemiology 1998; 9: 398-404.
16. Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000; 55: 11 58-1 166.
17. Schofield PW, Tang M, Marde K, et al. Alzheimer's disease after remote head injury: an incidence study. Journal of Neurology Neurosurgery and Psychiatry 1997; 62: 119-124.
18. Launer LJ, Andersen K. Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. Neurology 1999; 52: 78-84.
19. Nemetz PN, Leibson C, Naessens JM, et al. Traumatic brain injury and time to onset of Alzheimer's disease: A population-based study. American Journal of Epidemiology 1999; 149: 32-40.
20. Forette, F., Seux. M-L., Staessen, J.A, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
21. Whitlock G, MacMahon S, Anderson C, Neal B, Rodgers A, Chalmers J. Blood pressure lowering for the prevention of cognitive decline In patients with cerebrovascular disease, PROGRESS Management Committee. Perindopril Protection Against Recurrent Stroke Study. Clinical and Experimental Hypertension 1997; 19: 843-855.
22. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994: 308: 81-106.
23. Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multiinfarct dementia: a pilot study. Journal of the American Geriatrics Society 1989; 37: 549-555.
24. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular disease: a statement for healthcare professionals from the nutrition committee, American Heart Association. Circulation 1999; 99: 178-182.
25. Clarke R, Smit D, Jobst KA. Refsu H, Sutton L, Ueland PM. Folate, vitamin B1 2, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of Neurology 1998; 55: 1449-1455.
26. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia and Geriatric Cognitive Disorders 1999; 10: 12-20.
27. Hebert PR, Gaziano M, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials. Journal of the American Medical Association 1997; 278: 31 3-321.
28. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and risk of dementia. Lancet 2000; 356: 1627-1631.
29. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Archives of Neurology 2000; 57: 1439-1 443.
30. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999; 56: 303-308.
31. Sramek JJ. Veroff AE, Cutler NR. The status of ongoing trials for mild cognitive impairment. Expert Opinion on Investigational Drugs 2001 ; 10: 741-752.
32. Bonneux L, Barendregt JJ, Nusselder WJ. Van der Maas PJ. Preventing fatal diseases increases healthcare costs: cause elimination life table approach. British Medical Journal 1998; 31 6: 26-29.